TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34467454

Group type: EXPERIMENTAL
Intervention: Radiomics nomogram model combining radiomics signatures and clinical factors
Number of subjects: 203

Group type: COMPARATOR
Intervention: Radiomics model
Number of subjects: 203

Group type: COMPARATOR
Intervention: Clinical model
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Radiomics nomogram model
Number of subjects: 203
Study: 33940435

Group type: EXPERIMENTAL
Intervention: Provision of accurate and focused information about COVID-19 via phone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study: 33196485

Group type: EXPERIMENTAL
Intervention: Immediate oral refeeding (IORF) - low-fat-solid diet initiated immediately after hospital admission
Number of subjects: 131

Group type: COMPARATOR
Intervention: Conventional oral refeeding (CORF) - progressive oral diet restarted when clinical and laboratory parameters improved
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Immediate oral refeeding (IORF)
Number of subjects: 131
Study: 32560724

Group type: EXPERIMENTAL
Intervention: Saroglitazar 2 mg
Number of subjects: 1155

Group type: EXPERIMENTAL
Intervention: Saroglitazar 4 mg
Number of subjects: 1155

Group type: COMPARATOR
Intervention: Pioglitazone 30 mg
Number of subjects: 1155

Group type: EXPERIMENTAL
Intervention: Saroglitazar (2 mg and 4 mg) and Pioglitazone
Number of subjects: 1155
Study: 35385141

Group type: EXPERIMENTAL
Intervention: Cold spray
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: ShotBlocker
Number of subjects: 195

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 195

Group type: COMPARATOR
Intervention: Cold spray placebo
Number of subjects: 195

Group type: COMPARATOR
Intervention: ShotBlocker placebo
Number of subjects: 195
Study: 33594488

Group type: EXPERIMENTAL
Intervention: Metformin + Insulin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo + Insulin
Number of subjects: 0
Study: 32898188

Group type: EXPERIMENTAL
Intervention: Transcranial alternating current stimulation (tACS) at 30 Hz for 20 minutes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Transcranial alternating current stimulation (tACS) at 30 Hz
Number of subjects: 0
Study: 35901330

Group type: EXPERIMENTAL
Intervention: Chemotherapy (51.8% of patients), with paclitaxel/carboplatin as the most common regimen.
Number of subjects: 259
Study: 32731214

Group type: EXPERIMENTAL
Intervention: M‐BLI only
Number of subjects: 128

Group type: COMPARATOR
Intervention: M‐BLI with biopsy confirmation (M‐BLI‐BC)
Number of subjects: 128
Study: 35398872

Group type: EXPERIMENTAL
Intervention: Algorithm-based nursing intervention (ANI) for 2 months
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 54
Study: 33427969

Group type: EXPERIMENTAL
Intervention: Reactive jumps countermeasure (JUMP)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (CTRL)
Number of subjects: 20
Study: 32701928

Group type: EXPERIMENTAL
Intervention: Mepivacaine 2%
Number of subjects: 20

Group type: COMPARATOR
Intervention: Articaine 4%
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both anesthetics
Number of subjects: 20
Study: 35287698

Group type: EXPERIMENTAL
Intervention: Oxycodone + naloxone (up to 20 mg per day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 34740804

Group type: EXPERIMENTAL
Intervention: Female gender in asymptomatic patients undergoing CEA or CAS
Number of subjects: 106568

Group type: EXPERIMENTAL
Intervention: Female gender in symptomatic patients
Number of subjects: 106568

Group type: EXPERIMENTAL
Intervention: Female patients <75yo
Number of subjects: 106568

Group type: EXPERIMENTAL
Intervention: Female patients ≥75yo
Number of subjects: 106568

Group type: EXPERIMENTAL
Intervention: Female gender in asymptomatic patients undergoing CEA
Number of subjects: 106568

Group type: EXPERIMENTAL
Intervention: Female gender in symptomatic patients undergoing CEA
Number of subjects: 106568

Group type: COMPARATOR
Intervention: Female gender in patients undergoing CAS
Number of subjects: 106568
Study: 36300713

Group type: EXPERIMENTAL
Intervention: High serum interleukin 2 receptor (sIL‐2R) levels
Number of subjects: 340
Study: 34863253

Group type: EXPERIMENTAL
Intervention: Qualitative study exploring patient and health worker experiences
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Focus group discussions with patients, nurses, and counsellors
Number of subjects: 26
Study: 33247722

Group type: EXPERIMENTAL
Intervention: Aldosterone infusion (0.2 and 5 ng min‐1 [L leg volume]‐1 for 10 minutes)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Aldosterone infusion with coinfusion of NAC (125 mg kg‐1 hour‐1 followed by 25 mg kg‐1 hour‐1)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Aldosterone infusion (both groups)
Number of subjects: 26
Study: 32588971

Group type: EXPERIMENTAL
Intervention: Receiving amyloid positron emission tomography results
Number of subjects: 164
Study: 35148868

Group type: EXPERIMENTAL
Intervention: Culinary nutrition education intervention
Number of subjects: 83
Study: 34939083

Group type: EXPERIMENTAL
Intervention: Two-stage targeted minimum loss-based estimator
Number of subjects: 0

Group type: COMPARATOR
Intervention: Existing CRT estimators
Number of subjects: 0
Study: 36235571

Group type: EXPERIMENTAL
Intervention: 50 g erythritol
Number of subjects: 20

Group type: COMPARATOR
Intervention: 33.5 g sucrose
Number of subjects: 20

Group type: COMPARATOR
Intervention: 0.0558 g sucralose
Number of subjects: 20

Group type: COMPARATOR
Intervention: Tap water
Number of subjects: 20
Study: 32578066

Group type: EXPERIMENTAL
Intervention: Steroid group (hydrocortisone 500 mg before hepatic pedicle clamping, followed by 300 mg on POD 1, 200 mg on POD 2, and 100 mg on POD 3)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Control group (physiologic saline)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Steroid group
Number of subjects: 94

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 94
Study: 32396288

Group type: EXPERIMENTAL
Intervention: Resistance training 3 times per week (G3x)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Resistance training 2 times per week (G2x)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Both G2x and G3x
Number of subjects: 39
Study: 33185816

Group type: EXPERIMENTAL
Intervention: Short Message Service (SMS)
Number of subjects: 797

Group type: EXPERIMENTAL
Intervention: Voice Messages (VMS)
Number of subjects: 797

Group type: EXPERIMENTAL
Intervention: 2 VMS per week
Number of subjects: 797

Group type: EXPERIMENTAL
Intervention: Other frequencies (not specified)
Number of subjects: 797

Group type: EXPERIMENTAL
Intervention: Future programs participation
Number of subjects: 797
Study: 32458450

Group type: EXPERIMENTAL
Intervention: Oropharyngeal administration of mother's milk (OPAMM) prior to gavage feeding (0.2 mL of mother's milk before each feeding)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Oropharyngeal administration of mother's milk (OPAMM) prior to gavage feeding
Number of subjects: 40

Group type: COMPARATOR
Intervention: Regular gavage feeding
Number of subjects: 40
Study: 32770776

Group type: EXPERIMENTAL
Intervention: New model using PAPP-A measurements and maternal characteristics
Number of subjects: 60875

Group type: COMPARATOR
Intervention: NICE guidelines
Number of subjects: 60875
Study: 35728781

Group type: EXPERIMENTAL
Intervention: Prophylactic antibiotics (500 mg azithromycin for 1 dose and 2 g cefazolin every 8 hours for up to 3 doses)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Prophylactic antibiotics (in class III obesity subgroup)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Placebo (in class III obesity subgroup)
Number of subjects: 101
Study: 34107968

Group type: EXPERIMENTAL
Intervention: Nomogram model developed using multivariate logistic regression from training set (n = 616)
Number of subjects: 880
Study: 32277384

Group type: EXPERIMENTAL
Intervention: Financial support (up to 3 weekly financial transfers of $200 each)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control group (no financial support)
Number of subjects: 46
Study: 35536764

Group type: EXPERIMENTAL
Intervention: Febuxostat (40 mg or 80 mg once daily)
Number of subjects: 6190

Group type: COMPARATOR
Intervention: Allopurinol (titrated in 100‐mg increments from 200‐400 mg or 300‐600 mg)
Number of subjects: 6190

Group type: EXPERIMENTAL
Intervention: Febuxostat
Number of subjects: 6190

Group type: COMPARATOR
Intervention: Allopurinol
Number of subjects: 6190

Group type: EXPERIMENTAL
Intervention: Febuxostat and Allopurinol
Number of subjects: 6190
Study: 32701826

Group type: EXPERIMENTAL
Intervention: Moderate-intensity exercise
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: High-intensity exercise
Number of subjects: 55
Study: 32659235

Group type: EXPERIMENTAL
Intervention: Baseline RALE score
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Change in RALE score over time
Number of subjects: 135
Study: 35303474

Group type: EXPERIMENTAL
Intervention: Two midwives during the second stage of labour
Number of subjects: 3776

Group type: COMPARATOR
Intervention: One midwife during the second stage of labour
Number of subjects: 3776
Study: 33036058

Group type: EXPERIMENTAL
Intervention: 0.3% hyaluronic acid
Number of subjects: 20

Group type: COMPARATOR
Intervention: 0.1% hyaluronic acid
Number of subjects: 20

Group type: COMPARATOR
Intervention: 0.2% hyaluronic acid
Number of subjects: 20
Study: 36148748

Group type: EXPERIMENTAL
Intervention: Oral vitamin D3 supplementation (400 IU/day)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Sunlight exposure (40% body surface area for a minimum of 30 minutes/week)
Number of subjects: 80
Study: 33497912

Group type: EXPERIMENTAL
Intervention: Cognitive training intervention
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Booster sessions
Number of subjects: 50

Group type: COMPARATOR
Intervention: Entropy-based metric
Number of subjects: 50
Study: 33189807

Group type: EXPERIMENTAL
Intervention: Immediate coronary angiography
Number of subjects: 522

Group type: COMPARATOR
Intervention: Delayed coronary angiography
Number of subjects: 522

Group type: EXPERIMENTAL
Intervention: Significant coronary artery disease (CAD) in women
Number of subjects: 522

Group type: EXPERIMENTAL
Intervention: Significant coronary artery disease (CAD) in men
Number of subjects: 522
Study: 35968706

Group type: EXPERIMENTAL
Intervention: Early Rhythm Control (ERC)
Number of subjects: 1093

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 1093
Study: 33725800

Group type: EXPERIMENTAL
Intervention: dupilumab
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: topical pimecrolimus
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: topical tacrolimus
Number of subjects: 0

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 0
Study: 36074631

Group type: EXPERIMENTAL
Intervention: Power up Children's Psychological Immunity (PCPI)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 87
Study: 32275730

Group type: EXPERIMENTAL
Intervention: Peer tutoring program
Number of subjects: 376

Group type: COMPARATOR
Intervention: Control groups
Number of subjects: 376
Study: 36029727

Group type: EXPERIMENTAL
Intervention: Preterm pre-eclampsia
Number of subjects: 44
Study: 34163067

Group type: EXPERIMENTAL
Intervention: Very-low-calorie diet
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Post-diet microbiota transplantation to mice
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Weight loss
Number of subjects: 0
Study: 36201753

Group type: EXPERIMENTAL
Intervention: EstroSense®
Number of subjects: 148

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 148
Study: 33358263

Group type: EXPERIMENTAL
Intervention: 23-valent pneumococcal polysaccharide vaccine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 32030636

Group type: EXPERIMENTAL
Intervention: Cognitive rehabilitation program (1-hour sessions per week for 8 weeks)
Number of subjects: 20

Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 20
Study: 32008370

Group type: EXPERIMENTAL
Intervention: EjS‐PVP (Ejaculatory hood‐sparing photoselective vaporization of the prostate)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: EjS‐BPVP (Ejaculatory hood‐sparing bipolar button plasma vaporization of the prostate)
Number of subjects: 27

Group type: COMPARATOR
Intervention: EjS‐PVP
Number of subjects: 27

Group type: COMPARATOR
Intervention: EjS‐BPVP
Number of subjects: 27

Group type: COMPARATOR
Intervention: Both interventions
Number of subjects: 27
Study: 36173627

Group type: EXPERIMENTAL
Intervention: Follow-up of abnormal cancer screening test results
Number of subjects: 275

Group type: EXPERIMENTAL
Intervention: Follow-up of overdue abnormal cancer screening test results
Number of subjects: 275

Group type: EXPERIMENTAL
Intervention: Satisfaction with managing abnormal cancer screening test results
Number of subjects: 275

Group type: EXPERIMENTAL
Intervention: Barriers to follow-up of abnormal cancer screening test results
Number of subjects: 275
Study: 34109485

Group type: EXPERIMENTAL
Intervention: Brain connectivity markers identified using diffusion tensor imaging and resting-state functional MRI
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Random forest model constructed from the training group
Number of subjects: 131

Group type: COMPARATOR
Intervention: Five of nine markers
Number of subjects: 131
Study: 32819132

Group type: EXPERIMENTAL
Intervention: ALBI score
Number of subjects: 529

Group type: EXPERIMENTAL
Intervention: MELD score
Number of subjects: 529

Group type: EXPERIMENTAL
Intervention: CLIF-C ACLF score
Number of subjects: 529
Study: 34114408

Group type: EXPERIMENTAL
Intervention: Zhengyuan capsule (8-week regimen)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo capsule (8-week regimen)
Number of subjects: 0
Study: 32539805

Group type: EXPERIMENTAL
Intervention: Stereotactic ablative radiotherapy (SABR) followed by L19-IL2 therapy for oligo-metastatic patients; SABR to one (symptomatic) to a maximum of 5 lesions for poly-metastatic patients.
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Stereotactic ablative radiotherapy (SABR) combined with immunotherapy (L19-IL2).
Number of subjects: 126

Group type: COMPARATOR
Intervention: Standard of care (SOC) according to local protocol.
Number of subjects: 126
Study: 32082008

Group type: EXPERIMENTAL
Intervention: Labor Epidural Analgesia (EA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Labor Spinal Analgesia (SA)
Number of subjects: 0
Study: 34417708

Group type: EXPERIMENTAL
Intervention: Reduction in work hours
Number of subjects: 187
Study: 34131733

Group type: EXPERIMENTAL
Intervention: Intranasal insulin
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 32385720

Group type: EXPERIMENTAL
Intervention: 10% turmeric powder diet
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: 14% turmeric powder diet
Number of subjects: 5

Group type: COMPARATOR
Intervention: 0% turmeric powder diet (control)
Number of subjects: 5
Study: 36414402

Group type: EXPERIMENTAL
Intervention: Standard cancer care plus in-home palliative care
Number of subjects: 95

Group type: COMPARATOR
Intervention: Standard cancer care
Number of subjects: 95
Study: 34636853

Group type: EXPERIMENTAL
Intervention: UV‐C light plus standard environmental cleaning
Number of subjects: 302

Group type: COMPARATOR
Intervention: Standard environmental cleaning
Number of subjects: 302
Study: 33371058

Group type: COMPARATOR
Intervention: Low-dose meropenem (1g IV every 8 hours)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: High-dose meropenem (2g IV every 8 hours)
Number of subjects: 64
Study: 35465002

Group type: EXPERIMENTAL
Intervention: Nursing care in operating room combined with intraoperative heat preservation intervention
Number of subjects: 200

Group type: COMPARATOR
Intervention: Nursing care in operating room
Number of subjects: 200
Study: 33847098

Group type: EXPERIMENTAL
Intervention: Dietary-supplemented artichoke (Cynara scolymus L.) at 3g/kg in the diet of laying hens.
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group receiving 130 g/day of compound feed for laying hens without artichoke supplementation.
Number of subjects: 80
Study: 32242355

Group type: EXPERIMENTAL
Intervention: Urgent endoscopy within 6 hours after gastroenterologic consultation
Number of subjects: 516

Group type: COMPARATOR
Intervention: Early endoscopy between 6 and 24 hours after gastroenterologic consultation
Number of subjects: 516

Group type: EXPERIMENTAL
Intervention: Urgent endoscopy within 6 hours
Number of subjects: 516

Group type: COMPARATOR
Intervention: Early endoscopy between 6 and 24 hours
Number of subjects: 516
Study: 35709412

Group type: EXPERIMENTAL
Intervention: Four cycles of ifosfamide, vincristine, and actinomycin D (IVA) plus doxorubicin, five cycles of IVA, and 12 cycles of maintenance chemotherapy (low-dose cyclophosphamide and vinorelbine).
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Addition of bevacizumab to the same chemotherapy (in BERNIE study).
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Patients with ≤ 2 Oberlin risk factors (ORFs).
Number of subjects: 270
Study: 32450793

Group type: EXPERIMENTAL
Intervention: Hemodialysis (HD) days
Number of subjects: 195

Group type: COMPARATOR
Intervention: First non-HD days (>24 to ≤48 h after start HD)
Number of subjects: 195

Group type: COMPARATOR
Intervention: Second non-HD days (>48 to ≤72 h after start HD)
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: 2-h post-HD
Number of subjects: 195
Study: 34752913

Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 or 25mg with standard of care (SOC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard of care (SOC) alone
Number of subjects: 0
Study: 34076901

Group type: EXPERIMENTAL
Intervention: Ivermectin 12 mg once daily for 3 days plus standard care
Number of subjects: 164

Group type: COMPARATOR
Intervention: Standard care alone for 14 days
Number of subjects: 164
Study: 32080000

Group type: EXPERIMENTAL
Intervention: Intranasal ketamine
Number of subjects: 1102

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1102
Study: 34343735

Group type: EXPERIMENTAL
Intervention: Surface contact laser‐turbinectomy and NSB reduction using a 970 nm diode laser (Group 1)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Laser‐turbinectomy without NSB reduction (Group 2)
Number of subjects: 39
Study: 34060937

Group type: EXPERIMENTAL
Intervention: MET409 (farnesoid X receptor agonist)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: MET409
Number of subjects: 48
Study: 36231156

Group type: EXPERIMENTAL
Intervention: Speak Up Be Safe (SUBS) curriculum
Number of subjects: 2797

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 2797
Study: 32958468

Group type: EXPERIMENTAL
Intervention: Supervised exercise therapy and patient education (8-week program)
Number of subjects: 16499
Study: 33023488

Group type: EXPERIMENTAL
Intervention: Teriflunomide 14 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 36185085

Group type: EXPERIMENTAL
Intervention: Hewei Jiangni Decoction (HWJND) 81 g plus dummy omeprazole 20 mg daily for 8 weeks
Number of subjects: 128

Group type: COMPARATOR
Intervention: Dummy HWJND granules (81 g) plus omeprazole (20 mg)
Number of subjects: 128
Study: 32847567

Group type: EXPERIMENTAL
Intervention: Modified Bunnell suture technique (group B)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Bundle-to-bundle suture technique (group A)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 72
Study: 36242061

Group type: EXPERIMENTAL
Intervention: Kangyi Qiangshen Gong exercise prescription (KQG)
Number of subjects: 60

Group type: COMPARATOR
Intervention: World Health Organization instructed breathing techniques (BT)
Number of subjects: 60
Study: 34974512

Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR) distraction
Number of subjects: 20

Group type: COMPARATOR
Intervention: iPad distraction (active control)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Fear (across both groups)
Number of subjects: 20
Study: 35535708

Group type: EXPERIMENTAL
Intervention: Methenamine hippurate (1g twice daily)
Number of subjects: 240
Study: 36042251

Group type: EXPERIMENTAL
Intervention: Probiotic Lactobacillus rhamnosus HN001
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 32301701

Group type: EXPERIMENTAL
Intervention: Group A: 250 mL of 0.9% normal saline containing 2 g cefuroxime sodium 30 minutes before surgery
Number of subjects: 486

Group type: COMPARATOR
Intervention: Group C: cefuroxime only after returning to ward, once daily for 3 consecutive days
Number of subjects: 486

Group type: EXPERIMENTAL
Intervention: Group B: cefuroxime 30 minutes before surgery and 3 days after surgery
Number of subjects: 486
Study: 33359042

Group type: EXPERIMENTAL
Intervention: At-home treatment with 10% carbamide peroxide (2 h/day; 3 weeks)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: In-office treatment with 35% hydrogen peroxide (1/week; 3 weeks)
Number of subjects: 130

Group type: COMPARATOR
Intervention: At-home placebo
Number of subjects: 130

Group type: COMPARATOR
Intervention: In-office placebo
Number of subjects: 130
Study: 35794366

Group type: EXPERIMENTAL
Intervention: HW-CO2
Number of subjects: 85

Group type: COMPARATOR
Intervention: DC-CO2
Number of subjects: 85
Study: 34020445

Group type: EXPERIMENTAL
Intervention: Intensive weight loss lifestyle intervention based on an energy-restricted Mediterranean diet and physical activity promotion
Number of subjects: 362

Group type: COMPARATOR
Intervention: Non-energy-restricted Mediterranean diet
Number of subjects: 362

Group type: EXPERIMENTAL
Intervention: Intensive weight loss lifestyle intervention
Number of subjects: 362

Group type: EXPERIMENTAL
Intervention: Both intervention groups
Number of subjects: 362
Study: 36855259

Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT) for 4 weeks, 3 sessions per week
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control group (CON)
Number of subjects: 19
Study: 33108521

Group type: EXPERIMENTAL
Intervention: Cod (750 g/week)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Salmon (750 g/week)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Control (no fish intake)
Number of subjects: 76